A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma

Clinical Genitourinary Cancer

Volumn 10, Issue 3, 2012, Pages 153-158

  Amato, Robert ^a   Zhai, Jim ^b   Willis, James ^c   Saxena, Somyata ^a   Defoe, Melissa ^d  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b Methodist Hospital   (United States)

^c Ara/ST David's Imaging LP   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Intrapatient dose escalation; Metastatic renal cell carcinoma; Sorafenib

Indexed keywords

PLACEBO; SORAFENIB;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPNEA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HOSPITAL PATIENT; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; KIDNEY METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; OVERALL SURVIVAL; PAIN; PARANASAL SINUS DISEASE; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SINUS DRAINAGE; SKIN REDNESS; STOMATITIS; TOXICITY; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; TREATMENT OUTCOME;

EID: 84864997618     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2012.03.001     Document Type: Article

References (9)

1. S.M. Wilhelm, C. Carter, L. Tang BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression an angiogenesis Cancer Res 64 2004 7099 7109 (Pubitemid 39331023)
2. Y.S. Chang, J. Adnane, P.A. Trail Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models Cancer Chemother Pharmacol 59 2007 561 574 (Pubitemid 46295136)
3. S. Wilhelm, D.S. Chien BAY 43-9006: preclinical data Curr Pharm Des 8 2002 2255 2257 (Pubitemid 35189898)
4. D. Strumberg, D. Voliotis, J.G. Moeller Results of phase I pharmacokinetic and pharmacodynamic studies of the ref kinase inhibitor NEXAVAR in patients with solid tumors Int J Clin Pharmacol Ther 40 2002 580 581
5. Y.N. Wong, D. Rossignol, J.R. Rose Safety, pharmacokinetics and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study J Clin Pharmacol 43 7 2003 735 742 (Pubitemid 36759151)
6. M.J. Ratain, T. Eisen, W.M. Stadler Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2006 2505 2512 (Pubitemid 46630627)
7. B. Escudier, T. Eisen, W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134 (Pubitemid 46089673)
8. D. Strumberg, H. Richly, R.A. Hilger Phase I clinical and pharmacokinetic study of the novel ref kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors J Clin Oncol 23 2005 965 972 (Pubitemid 46202316)
9. M.E. Gore, R.J. Jones, A. Ravaud Efficacy and safety of intrapatient dose escalation of sorafenib as first-line treatment for metastatic renal cell carcinoma (mRCC) J Clin Oncol 29 suppl 2011 Abstract 4609